For people living with type 1 diabetes, every day brings a series of calculations designed to strike a fine balance: inject just enough insulin to prevent sky-high blood glucose, without tipping the scales enough to cause dangerous hypoglycemia. Each time a patient hits on the just-right Goldilocks dose can feel like a minor victory.
Now, medicine could be one step closer to slowing down or possibly even preventing the disease. In a recent phase 2 trial, a 2-week intravenous course of an investigational drug called teplizumab delayed progression to type 1 diabetes compared with a placebo in people at high risk of the disease. The study was conducted by TrialNet, a federally funded research consortium that screens and monitors relatives of people with type 1 diabetes.
Abbasi J. Type 1 Diabetes Advances Could Pave Way for Prevention. JAMA. Published online August 21, 2019322(10):912–914. doi:10.1001/jama.2019.10432
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: